- Abbott reports Q3 results in line with forecasts
- However, concerns about tariffs push share prices down ahead of Wall Street opening
- Abbott reports Q3 results in line with forecasts
- However, concerns about tariffs push share prices down ahead of Wall Street opening
Abbott (ABT.US) published a solid report for the third quarter of 2025, presenting results in line with market expectations, although the context surrounding the company was not free from tensions resulting from the threat of new trade tariffs from the Trump administration.
In Q3, Abbott reported adjusted earnings per share (EPS) of $1.30 and revenues of $11.4 billion, both in line with analyst consensus. Organic sales growth was 5.5% y/y, while sales in the Medical Devices segment grew by as much as 15%. The company reported a mixed annual EPS forecast of $5.12–5.18 (expected $5.15; the upper limit, which was $5.20, was lowered) and expects organic sales growth in 2025 to be 7.5-8% (excluding COVID-19 tests; 7.74% was expected).
Despite the figures being in line with forecasts, concerns about potential US tariffs on medical devices had a negative impact on the stock price, which fell by more than 4% before the opening of Wall Street sesion. At the same time, Abbott is not slowing down its investments in the US, expanding production and adapting to new regulatory challenges.
Abbott Q3 2025: earnings, sales, and forecasts. Source: XTB
Market Wrap: European software stocks keep indices near record highs. Dollar gives up this week's gains (14.08.2026)
Reddit joins the S&P 500, shares surge 12% 📈 From a niche forum to the heart of Wall Street
Daily Summary: S&P 500 at a New ATH (13.08.2026)
US Open: S&P 500 close to highs - as September Fed hike chances fall (13.08.2026)
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
